SCHEMBL653172

SCHEMBL653172

NC(=S)Nc1ccc(Cl)cc1Cl

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
LMNA P02545 7/20 0.57
NPC1 O15118 5/20 0.57
RAB9A P51151 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
GAA P10253 2/20 0.57
HTT P42858 2/20 0.57
ALOX12 P18054 2/20 0.55
MEN1 O00255 3/20 0.54
MAPT P10636 3/20 0.54
KMT2A Q03164 3/20 0.54
HPGD P15428 1/20 0.54
TP53 P04637 1/20 0.51
XBP1 P17861 1/20 0.51
CYP1A2 P05177 1/20 0.51
MAPK1 P28482 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29639365 1.00 ALDH1A1 (0.61) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL2588962 0.84 IDO1 (0.68) ALDH1A1LMNAGAAALOX12MEN1
SCHEMBL29639348 0.84 IDO1 (0.68) ALDH1A1LMNAGAAALOX12MEN1
SCHEMBL31388374 0.83 ALDH1A1 (0.82) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL11136324 0.83 ALDH1A1 (0.59) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL7710332 0.81 IDO1 (0.74) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL6833378 0.81 POLB (0.51) ALDH1A1NPC1MAPTKMT2ANPSR1
SCHEMBL11164506 0.81 RAB9A (0.51) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL6929125 0.81 GAA (0.70) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL7710335 0.81 GAA (0.70) ALDH1A1LMNANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114432901-B Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof 中国石油化工股份有限公司 2023-04-11 CN claimed
CN-114432901-A Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof 中国石油化工股份有限公司 2022-05-06 CN claimed
US-20060281725-A1 Agents and crystals for improving excretory potency of urinary bladder ISIHARA YUJI 2006-12-14 US claimed
EP-1604653-A1 Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder Takeda Pharmaceutical Company Limited (JP) 2005-12-14 EP claimed
US-20040116457-A1 Agents for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-06-17 US claimed
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-11-28 US claimed
EP-1118322-A1 DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH Takeda Chemical Industries, Ltd. (JP) 2001-07-25 EP claimed
US-12630515-B2 Small molecule prostagladin transport inhibitors ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2026-05-19 US disclosed
EP-4054608-B1 SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS ALBERT EINSTEIN COLLEGE MEDICINE (US) 2026-03-04 EP disclosed
CN-117164480-A Method for preparing cyanamide and mercaptan 华南理工大学 2023-12-05 CN disclosed
US-20230263167-A1 METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-08-24 US disclosed
US-11700855-B2 Method for preventing or reducing growth of a microorganism on a surface IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-07-18 US disclosed
CN-114432901-B Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof 中国石油化工股份有限公司 2023-04-11 CN disclosed
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-11-28 US disclosed
EP-1122252-A1 NITROGENOUS FUSED HETEROCYCLE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND AGENTS CONTAINING THE SAME Takeda Chemical Industries, Ltd. (JP) 2001-08-08 EP disclosed
EP-1118322-A1 DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH Takeda Chemical Industries, Ltd. (JP) 2001-07-25 EP disclosed
EP-0975624-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS Takeda Chemical Industries, Ltd. (JP) 2000-02-02 EP disclosed
WO-1998046590-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-22 WO disclosed
US-5000775-A 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes MONSANTO COMPANY (US) 1991-03-19 US disclosed
US-4262005-A CONTROLLING ECTOPARASITES WHICH ATTACK CATTLE AND PIGS THE BOOTS COMPANY LIMITED (GB) 1981-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BPHL, BCHE ALDH1A1 1185/4885LMNA 3299/4885NPC1 1932/4885
US-20060281725-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BCHE, PDE7A ALDH1A1 1245/4885LMNA 3396/4885NPC1 2214/4885
US-12630515-B2 Small molecule prostagladin transport inhibitors PTGER1, PTGS1, PTGIR ALDH1A1 1715/4885LMNA 2813/4885NPC1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.